ASXL1 and acute myeloid leukemia: To date, there are no approved precision therapies for patients with ASXL1 variants, and careful modulation of the canonical Wnt signaling pathway represents a potential therapeutic option for BOS patients and for AML-ASXL1. Studies in preclinical models, such as mice and rats, are needed to understand the interplay between these Wnt-signaling pathways and ASXL1 variants and potential off target effects.